- Signs for push-out forces
- After two years on the job
- Laud, praise, thanks, words of regret and good wishes for Glucksmann
- Position is currently not filled
- Glucksmann spoke at length and said 79 words
(exechange) — Cambridge, Massachusetts, March 03, 2017 — Sandra Glucksmann, operating chief of Editas, leaves. It is a change at short notice. As announced by Editas Medicine, Inc. in a news release and in a regulatory filing published on Friday, March 03, 2017, Alexandra (Sandra) Glucksmann, Chief Operating Officer, leaves the genome editing company in a surprising move after two years on the job, effective March 31, 2017.
In many companies, the chief operating post is a steppingstone to the CEO suite.
Editas did not name a replacement for the position of Chief Operating Officer.
No reason given
In the announcement, Editas did not explicitly explain the reason for Glucksmann’s imminent move, opening the door for speculation.
“Employment with the Company will terminate”
Editas said: “On February 28, 2017, Editas Medicine, Inc., … and Alexandra Glucksmann, Ph.D., Chief Operating Officer of the Company, agreed that Dr. Glucksmann’s employment with the Company will terminate effective March 31, 2017.”
Precise information about the future plans of Glucksmann was not immediately available.
Share price rise since November 2016
The change follows a rise in the share price of Editas Medicine, Inc. since November 2016.
CEO: Katrine Bosley
Katrine Bosley serves as CEO of Editas Medicine, Inc. Bosley joined Editas Medicine as President Chief Executive Officer in 2014, shortly after the company was founded.
On the job as COO since 2015
Alexandra Glucksmann has been Chief Operating Officer at Editas Medicine Inc. since April 2015.
Over the years, she has been responsible for managing the Company’s daily operations as well as developing Editas Medicine’s early pipeline strategy and business growth strategies.
Glucksmann joined Editas Medicine in November 2013.
Prior to joining Editas Medicine, Glucksmann was senior vice president of research and business operations from 2006 until June 2013 at Cerulean Pharma, a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products.
There, she was a founding employee and key contributor to all aspects of building the company, including setting strategy, analyzing product development opportunities, cultivating platform and product partnership prospects and participating in fundraising activities.
Prior to joining Cerulean in 2006, Glucksmann spent 13 years at Millennium Pharmaceuticals, which she joined in 1993 as one of its first scientists.
At Millennium, she held a series of positions with increasing responsibility and was critical in helping Millennium evolve from a genomics research-focused organization to a fully integrated pharmaceuticals company with marketed products.
Her division played an integral role in Millennium’s numerous large pharma collaborations, which generated more than $1.8 billion in funding for the company.
She serves as the chairperson of the Board of Directors of Women Entrepreneurs in Science and Technology (WEST).
Glucksmann was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago and a B.S. in molecular biology from the University of Wisconsin.
Signs for push-out forces
It is not completely certain what forces eventually triggered Alexandra Glucksmann’s move.
The Push-out Score™ determined by exechange suggests that push-out forces may have contributed to the management change.
Read the full story in the exechange report 10.2017 ($).